Horizon Pharma Inc. (HZNP) Upgraded at Vetr Inc.
Horizon Pharma Inc. (NASDAQ:HZNP) was upgraded by investment analysts at Vetr from a “buy” rating to a “strong-buy” rating in a research note issued on Monday.
Other analysts have also issued reports about the stock. Mizuho reissued a “buy” rating and set a $30.00 target price (up from $24.00) on shares of Horizon Pharma in a research note on Wednesday, August 10th. Brean Capital reissued a “buy” rating and set a $30.00 target price on shares of Horizon Pharma in a research note on Thursday, July 14th. Morgan Stanley raised shares of Horizon Pharma from an “underweight” rating to an “equal weight” rating and set a $24.00 target price for the company in a research note on Monday, July 11th. Zacks Investment Research downgraded shares of Horizon Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, July 12th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $30.00 price target on shares of Horizon Pharma in a research report on Tuesday, September 13th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $30.00.
Shares of Horizon Pharma (NASDAQ:HZNP) traded up 1.60% during mid-day trading on Monday, hitting $18.42. 906,678 shares of the stock traded hands. The stock has a 50-day moving average of $19.72 and a 200-day moving average of $17.66. The company’s market cap is $2.96 billion. Horizon Pharma has a 52 week low of $12.86 and a 52 week high of $23.70.
Horizon Pharma (NASDAQ:HZNP) last released its earnings results on Monday, August 8th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.50 by $0.12. Horizon Pharma had a negative net margin of 0.34% and a positive return on equity of 23.46%. The business earned $257.40 million during the quarter, compared to analyst estimates of $235.43 million. During the same period in the prior year, the business earned $0.39 earnings per share. The business’s quarterly revenue was up 48.9% on a year-over-year basis. Analysts anticipate that Horizon Pharma will post $2.15 EPS for the current year.
In other news, EVP Jeffrey W. Sherman sold 2,900 shares of the stock in a transaction on Tuesday, August 2nd. The shares were sold at an average price of $20.00, for a total transaction of $58,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 2.10% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in HZNP. Canada Pension Plan Investment Board acquired a new position in shares of Horizon Pharma during the first quarter valued at approximately $114,000. Societe Generale purchased a new position in Horizon Pharma during the second quarter worth about $117,000. SG Americas Securities LLC purchased a new position in Horizon Pharma during the second quarter worth about $117,000. Nuveen Asset Management LLC purchased a new position in Horizon Pharma during the second quarter worth about $176,000. Finally, Profund Advisors LLC purchased a new position in Horizon Pharma during the second quarter worth about $194,000. Institutional investors own 85.25% of the company’s stock.
About Horizon Pharma
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.
Receive News & Stock Ratings for Horizon Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma Inc. and related stocks with our FREE daily email newsletter.